Novo Nordisk A/S $NVO Shares Sold by Teamwork Financial Advisors LLC

Key Points

• Teamwork Financial Advisors LLC reduced its holdings in Novo Nordisk A/S by 42.3% in the second quarter, retaining 18,388 shares worth approximately $1.27 million.
• Novo Nordisk A/S recently reported $0.97 earnings per share for the quarter, exceeding expectations, and has a current market capitalization of $245.31 billion.
• The firm announced a semi-annual dividend of $0.4119 per share, representing a yield of 240.0%, with a payout ratio of 22.53%.

Teamwork Financial Advisors LLC lessened its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 42.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,388 shares of the company's stock after selling 13,495 shares during the quarter. Teamwork Financial Advisors LLC's holdings in Novo Nordisk A/S were worth $1,269,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of NVO. First Hawaiian Bank lifted its holdings in shares of Novo Nordisk A/S by 0.6% during the first quarter. First Hawaiian Bank now owns 22,401 shares of the company's stock worth $1,556,000 after purchasing an additional 142 shares during the period. Anchor Investment Management LLC increased its holdings in Novo Nordisk A/S by 1.1% in the 1st quarter. Anchor Investment Management LLC now owns 13,597 shares of the company's stock worth $944,000 after buying an additional 150 shares during the period. Xponance Inc. raised its position in Novo Nordisk A/S by 5.0% during the 1st quarter. Xponance Inc. now owns 3,314 shares of the company's stock worth $230,000 after buying an additional 158 shares during the last quarter. Foster Dykema Cabot & Partners LLC lifted its stake in Novo Nordisk A/S by 3.8% during the 1st quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company's stock valued at $319,000 after acquiring an additional 166 shares during the period. Finally, 180 Wealth Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 3.6% in the 1st quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company's stock valued at $348,000 after acquiring an additional 173 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 1.2%

NVO opened at $54.94 on Friday. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $138.22. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The company has a fifty day moving average of $57.96 and a two-hundred day moving average of $66.33. The stock has a market capitalization of $245.31 billion, a price-to-earnings ratio of 15.09, a PEG ratio of 2.06 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. On average, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 22.53%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on NVO shares. Zacks Research cut shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a report on Wednesday, August 20th. BNP Paribas Exane raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price target on the stock in a report on Wednesday, August 13th. Wall Street Zen lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, September 9th. Finally, BNP Paribas upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research note on Wednesday, August 13th. Four investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S presently has an average rating of "Hold" and a consensus price target of $81.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.